ATH 33.3% 0.4¢ alterity therapeutics limited

3 bagger, page-2

  1. 664 Posts.
    This has the look of an over-bought over-hyped biotech spike, triggered by the release of animal research that seeks to find a scientific basis for the Phase IIa trial results previously published.

    All good research of course, but the translation into the market at this particular moment seems well OTT.

    I suspect American desperation for an AD cure is driving this - it's a tabloid illness under an intense media spotlight.

    There will be shirts (and more) lost in this spike. Take care.

 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.